RAC | Jotup

Simon Patterson Joins GoodRx Board of Directors

Retrieved on:

Donnerstag, Mai 30, 2024

Women, Seniors, Men, Family, Health, Consumer, Pharmaceutical, Retail, Online Retail, Intelsat, Skype, RAC, Multiplan, ZPG, FlixBus, Silver, Dell Technologies

GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced the election of Simon Patterson to its Board of Directors.

Key Points:

GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced the election of Simon Patterson to its Board of Directors.
Currently leading EMEA operations for the technology investment firm Silver Lake, Mr. Patterson brings to GoodRx decades of technology, strategy and management experience.
Mr. Patterson also serves on the boards of IVC Evidensia, New Zealand Rugby Commercial, RAC, and ZPG, and previously served on the boards of Cegid, Dell Technologies, FlixBus, Gerson Lehrman Group, Intelsat, MultiPlan and Skype.
“We believe Mr. Patterson’s significant expertise in finance and management, formed by his extensive experience operating, advising and investing in high-growth technology companies, will be a strong asset to GoodRx,” said Trevor Bezdek, GoodRx co-founder and Chairman of the Board.

Performant Financial Corporation Announces Financial Results for First Quarter 2024

Retrieved on:

Dienstag, Mai 7, 2024

Healthcare revenues in the first quarter of 2024 were $25.8 million, an increase of approximately 13% from $22.9 million in the prior year period.

Key Points:

Healthcare revenues in the first quarter of 2024 were $25.8 million, an increase of approximately 13% from $22.9 million in the prior year period.
Within healthcare, claims-based services revenue in the first quarter of 2024 was $12.4 million, while revenue from eligibility-based services in the first quarter was $13.4 million.
“The RecordsOne technology asset acquisition, plus strong financial and operational results in the first quarter, are encouraging for our longer term growth strategy,” said Rohit Ramchandani, Chief Financial Officer.
The Company will hold a conference call to discuss its first quarter 2024 results today at 5:00 p.m. Eastern.

Rimsys Launches Community-Driven Regulatory Intelligence

Retrieved on:

Montag, Mai 6, 2024

Medical Devices, Health, Technology, Health Technology, Software, RAPS, RAC, 2005 in television, Legislation, UDI

Rimsys, a leading regulatory information management software for the medtech industry, announced today the beta launch of its community-driven, centralized hub for global regulatory intelligence data, Rimsys Intel.

Key Points:

Rimsys, a leading regulatory information management software for the medtech industry, announced today the beta launch of its community-driven, centralized hub for global regulatory intelligence data, Rimsys Intel.
Rimsys Intel builds upon Rimsys’ mission of increasing the availability of life-changing medical technologies by giving users free access to regulatory intelligence, including regulatory affiliations, legislation, UDI requirements, risk class information for medical devices and IVDs, in addition to market access requirements for each regulated country.
“As part of our core company value to empower each other, Rimsys believes that regulatory intelligence should be easily accessible and free.
To help keep Rimsys Intel up to date amid evolving global regulations, Rimsys is engaging RAPS Regulatory Affairs Certificate (RAC) holders.

Furologee Reveals Gaming Desk Impact on Player Performance Through Innovative Survey

Retrieved on:

Freitag, April 26, 2024

Online, MOBA, FPS, RAC, USB, Multiplayer online battle arena, Peter Hancock (professor), Video game

This revelation comes as gaming desks become increasingly essential in enhancing the gaming experience, parallel to the meteoric rise in gaming popularity.

Key Points:

This revelation comes as gaming desks become increasingly essential in enhancing the gaming experience, parallel to the meteoric rise in gaming popularity.
Project leader Frank spearheaded a survey involving 200 dedicated gamers to assess the effects of different gaming desk designs on gameplay.
The L-shaped computer desk emerged as a preferred choice across all genres, indicating its versatility and potential to enhance gaming performance.
Furologee is committed to providing gamers with innovative and superior gaming furniture that caters to their unique needs.

Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor

Retrieved on:

Mittwoch, April 24, 2024

Western University, University, Ecosystem, Tanimoto, Chairperson, Ivey Business School, Disease, RAC, Therapy, Patient, Chemistry, TRIO, Lethbridge, Biology, Pharmacy, Drug discovery, Growth, Medical device

LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the appointment of Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor. In this role, Dr. Aspeslet will provide strategic guidance and support to the company's executive team as they continue to scale their AI-driven drug discovery platform and advance their pipeline of novel therapeutics.

Key Points:

LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the appointment of Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor.
Dr. Aspeslet brings over 25 years of progressive leadership and management experience in the life sciences industry.
"We are thrilled to welcome Dr. Aspeslet to the Model Medicines team," said Dr. Daniel Haders, CEO and Founder of Model Medicines.
"Throughout my career, I have witnessed the immense challenges and opportunities in bringing novel therapeutics to patients in need.

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Retrieved on:

Montag, April 8, 2024

Shingles, Editas Medicine, Regulatory affairs, Bristol Myers Squibb, Doctor of Philosophy, MBA, Rutgers University, Immunization, Johnson & Johnson, Allergan, RAC, Vaccine, Purdue University, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.

Key Points:

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.
“We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.”
Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally.
“I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li.
Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer.

Rumble Reports Fourth Quarter and Full Year 2023 Results

Retrieved on:

Mittwoch, März 27, 2024

Research, MAU, Acquisition, Interview, Software, Insurance, News, GA4, Maus, RAC, Marketing, Advertising, Video game

LONGBOAT KEY, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Rumble Inc. (Nasdaq: RUM) ("Rumble" or the "Company”), the video sharing platform and cloud services provider, today announced financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points:

For the fourth quarter of 2023, revenue was $20.4 million compared to $20.0 million in the fourth quarter of 2022, an increase of 2%.
Cost of services was $39.5 million for the quarter compared to $23.5 million in the fourth quarter of 2022.
General and administrative expense was $9.6 million for the quarter, compared to $9.9 million in the fourth quarter of 2022.
Research and development expense was $3.6 million for the quarter, compared to $2.6 million in the fourth quarter of 2022.

Kymanox® to Consolidate Brands of Acquired Companies

Retrieved on:

Dienstag, März 12, 2024

Innovation, Growth, Human factors and ergonomics, Commercialization, Communication, Name, Product design, Knowledge, CISS, EMA, Doctor of Philosophy, Engineering, RAC, FDA, Sales

Morrisville, North Carolina USA,, March 12, 2024 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services company exclusively serving the life sciences industry, announced today that the company will consolidate the brands of four recently acquired companies into the Kymanox brand.

Key Points:

Morrisville, North Carolina USA,, March 12, 2024 (GLOBE NEWSWIRE) -- Kymanox Corporation (“Kymanox”), a professional services company exclusively serving the life sciences industry, announced today that the company will consolidate the brands of four recently acquired companies into the Kymanox brand.
These companies include Neuma, based in King of Prussia, PA, Agilis Consulting Group, based in Cincinnati, OH, and Europe-based Anteris Helvetia and Anteris Medical.
“We are excited to consolidate these amazing companies into one brand to facilitate the rapid response our customers need in today’s complex business environment,” commented Matt Neighoff, Chief Commercial Officer at Kymanox.
“This consolidation reflects our company’s evolution as we prepare for increased global growth, continued support of biopharma and medical device companies, and deployment of innovative solutions.”

CyberSaint Announces $21M Series A to Accelerate Global Expansion

Retrieved on:

Mittwoch, März 20, 2024

CyberSaint , the leader in cyber risk management, today announced the company has raised $21M in Series A funding led by Riverside Acceleration Capital (RAC).

Key Points:

CyberSaint , the leader in cyber risk management, today announced the company has raised $21M in Series A funding led by Riverside Acceleration Capital (RAC).
The funding will build on customer momentum, accelerate market expansion, and continue the innovation of CyberSaint’s CyberStrong platform powered by its patented Artificial Intelligence (AI) technology.
CyberStrong enables enterprises to master their cyber risk posture and drive executive alignment by automating compliance and translating cyber risk into financial terms.
It is imperative that optimizing cyber risk posture is elevated to a business-critical level," stated Jerry Layden, CEO of CyberSaint.

Countdown to Crunch Time: How Early and Continual Regulatory Engagement Leads to Regulatory and Commercial Success, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Donnerstag, März 28, 2024

Innovation, MBA, Regulatory science, RAC, Business operations, Risk management

TORONTO, March 28, 2024 /PRNewswire-PRWeb/ -- In the webinar "Countdown to Crunch Time: How Early and Continual Regulatory Engagement Leads to Regulatory and Commercial Success," industry-leading regulators with extensive experience in both the biopharma and the CRO space engage in a not-to-be-missed, dynamic conversation. Participants will uncover vital strategies for navigating regulatory pathways seamlessly. By avoiding common pitfalls that could jeopardize submission deadlines, attendees will gain invaluable insights into safeguarding project timelines.

Key Points:

By avoiding common pitfalls that could jeopardize submission deadlines, attendees will gain invaluable insights into safeguarding project timelines.
TORONTO, March 28, 2024 /PRNewswire-PRWeb/ -- In the webinar "Countdown to Crunch Time: How Early and Continual Regulatory Engagement Leads to Regulatory and Commercial Success," industry-leading regulators with extensive experience in both the biopharma and the CRO space engage in a not-to-be-missed, dynamic conversation.
This webinar will shed light on the often-overlooked advantages of early and continual engagement with regulatory agencies and how proactive collaborative efforts in the early stages can significantly enhance efficiency and mitigate risks.
Register for this webinar today to gain insights into the advantages of early and continual regulatory engagement.